Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/r DLBCL) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Diffuse large B-cell lymphoma (DLBCL) is the most prevalent form of non-Hodgkin lymphoma (NHL), characterized by its diverse nature in terms of molecular changes, appearance, clinical behavior, and response to treatment. DLBCL, being highly aggressive, proliferates vigorously, affecting both lymph nodes and extranodal sites like the stomach, testis, and CNS. Relapse affects about 25–30% of DLBCL patients, with 10% experiencing resistance to treatment. Most relapses occur within two years of diagnosis, and many patients can't receive CAR T-cell therapy due to health issues or logistical challenges. For over two decades, the standard treatment for eligible patients with relapsed or refractory DLBCL has involved a second-line chemoimmunotherapy followed by autologous hematopoietic stem cell transplantation (AHCT). However, AHCT can cure only a minority, as most are ineligible due to age, health concerns, or resistance to second-line treatment. Nevertheless, some DLBCL patients still experience relapse after five years, often related to a favorable International Prognostic Index (IPI) score, limited-stage disease, and initial extranodal involvement. Survival rates have improved over time, with the latest 5-year relative survival rate being 62.0% in the United States and 55.4% in Europe. More than 50% of advanced-stage de novo DLBCL patients achieve a cure with rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, depending on the number of adverse prognostic factors from the International Prognostic Score (IPI), 20% to 50% of DLBCL patients are either refractory to R-CHOP or experience relapse after achieving complete response (CR). The FDA has approved Epkinly (epcoritamab-bysp) injection to treat adult patients with relapsed or refractory DLBCL, including cases originating from indolent lymphoma and high-grade B‑cell lymphoma after two or more prior systemic therapies. Epkinly is administered subcutaneously in 28-day cycles until disease progression or unacceptable toxicity.

·       Approximately 50 to 60% of DLBCL patients attain and sustain complete remission following initial treatment, 30 to 40% experience relapse, and 10% face treatment-resistant disease.

·       The occurrence of Double-Expressor Lymphoma (DEL) is more frequent in relapsed or refractory DLBCL (45%) compared to primary DLBCL (20–35%), and it is associated with poorer outcomes. Moreover, DHITsig-positive cases are more prevalent (60%) in diagnostic samples from relapsed DLBCL patients compared to those who do not experience relapse (30%).

 

Thelansis’s “Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/r DLBCL) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/r DLBCL) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/r DLBCL) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/r DLBCL) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/r DLBCL) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/r DLBCL), Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/r DLBCL) market outlook, Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/r DLBCL) competitive landscape, Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/r DLBCL) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)